TABLE 2

Relative affinities of various opioid agonists and antagonists for the wild-type and third intracellular loop deletion mutant receptors

Competition binding studies were carried out with membranes isolated from HEK293 cells stably expressing the WT and mutant receptors as described under Materials and Methods. For i3-1, the HEK293cells expressing this mutant receptor were treated with 10 μM naloxone for 48 h before membrane preparation. Binding data were analyzed using the GraphPad Prism program. Results were reported for two affinity states in cases when the two-site fit were significantly better than the one-site fit as defined by the program, p < 0.05. For two-site fits, KH and KL represented the Ki values of the high- and low-affinity states, respectively. The values in parentheses represent the percentage of the total receptor in the high-affinity state. Data represent mean ± S.E.M. of two (when Ki values were similar to WT) to four (when Ki values were different from WT) experiments in duplicates.
Receptor
CTOP Ki
Naloxone Ki
DAMGO
Morphine
PL017
KH
KL
KH
KL
KH
KL
nM nM nM nM
WT 9.7 ± 1.4 4.4 ± 0.63 1.4 ± 0.44 (48 ± 4) 140 ± 30 2.5 ± 0.48 (43 ± 4) 170 ± 6 11 ± 1.5 (36 ± 7) 330 ± 0
i3-1 N.D. N.D. 300 ± 80* N.D. N.D. N.D. N.D.
i3-2 10 ± 2.7 7.1 ± 0.23* 2.3 ± 1.7 (23 ± 1)* 100 ± 10 5.7 ± 1.3* (49 ± 9) 390 ± 170 7.9 ± 5.8 (23 ± 4) 540 ± 50
i3-3 12 ± 7.7 1.3 ± 0.52* 1.1 ± 0.56 (51 ± 3) 100 ± 10 0.93 ± 0.31 (56 ± 2) 110 ± 70 15 ± 9.1 (47 ± 12) 410 ± 270
i3-4 5.2 ± 0.13* 4.9 ± 0.41 0.27 ± 0.1* (20 ± 5)* 80 ± 30 7.4 ± 3.9 (47 ± 3) 330 ± 90 2.4 ± 1.6* (29 ± 8) 390 ± 60
i3-5 5.2 ± 1.1* 13 ± 2.0* 390 ± 60* 550 ± 30* N.D. N.D.
5A
22 ± 4.9*
15 ± 6.5*

60 ± 20*

180 ± 40
N.D.
N.D.
  • N.D., not determined; WT, wild-type.

  • * Signifies statistical significant different (p < 0.05) when comparing the mutants with the wild-type receptor using student unpaired t test.